Activation of adenosine A2A receptor reduces osteoclast formation via PKA- and ERK1/2-mediated suppression of NFκB nuclear translocation

British Journal of Pharmacology

Volumn 169, Issue 6, 2013, Pages 1372-1388

  Mediero, Aránzazu ^a   Perez Aso, Miguel ^a   Cronstein, Bruce N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adenosine A2A receptor; ERK1 2; osteoclast inhibition; p50 p105 NF B; PKA

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENZYME ACTIVATOR; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P50; SHORT HAIRPIN RNA;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE TURNOVER; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE SILENCING; MACROPHAGE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADENOSINE; ADENOSINE A2 RECEPTOR AGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL NUCLEUS; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNITS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; NF-KAPPA B P50 SUBUNIT; OSTEOCLASTS; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; RECEPTOR, ADENOSINE A2A; TRANSCRIPTION FACTOR RELA;

EID: 84879324699     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12227     Document Type: Article

References (46)

1. Blair HC, Robinson LJ, Zaidi M, (2005). Osteoclast signalling pathways. Biochem Biophys Res Commun 328: 728-738.
2. Bohm C, Hayer S, Kilian A, Zaiss MM, Finger S, Hess A, et al. (2009). The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss. J Immunol 183: 5938-5947.
3. Boyce BF, Yao Z, Xing L, (2009). Osteoclasts have multiple roles in bone in addition to bone resorption. Crit Rev Eukaryot Gene Expr 19: 171-180.
4. van Calker D, Muller M, Hamprecht B, (1979). Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 33: 999-1005.
5. Chan ES, Cronstein BN, (2010). Methotrexate-how does it really work? Nat Rev Rheumatol 6: 175-178.
6. Che J, Chan ES, Cronstein BN, (2007). Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2 signaling cascade or p38 mitogen-activated protein kinase signaling pathway. Mol Pharmacol 72: 1626-1636.
7. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, et al. (1999). A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19: 9192-9200.
8. Cheng B, Li J, Du J, Lv X, Weng L, Ling C, (2012). Ginsenoside Rb1 inhibits osteoclastogenesis by modulating NF-kappaB and MAPKs pathways. Food Chem Toxicol 50: 1610-1615.
9. Cronstein BN, Naime D, Ostad E, (1993). The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92: 2675-2682.
10. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, et al. (1997). Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11: 3482-3496.
11. Fredholm BB, Irenius E, Kull B, Schulte G, (2001). Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61: 443-448.
12. Fredholm BB, Ijzerman AP, Jacobson KA, Linden J, Muller CE, (2011). International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63: 1-34.
13. Hasko G, Linden J, Cronstein B, Pacher P, (2008). Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7: 759-770.
14. He W, Cronstein BN, (2012). Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling. Purinergic Signal 8: 327-337.
15. He Y, Staser K, Rhodes SD, Liu Y, Wu X, Park SJ, et al. (2011). Erk1 positively regulates osteoclast differentiation and bone resorptive activity. PLoS ONE 6: e24780.
16. Hirano D, Aoki Y, Ogasawara H, Kodama H, Waga I, Sakanaka C, et al. (1996). Functional coupling of adenosine A2a receptor to inhibition of the mitogen-activated protein kinase cascade in Chinese hamster ovary cells. Biochem J 316 (Pt 1): 81-86.
17. Hirata K, Taki H, Shinoda K, Hounoki H, Miyahara T, Tobe K, et al. (2010). Inhibition of tumor progression locus 2 protein kinase suppresses receptor activator of nuclear factor-kappaB ligand-induced osteoclastogenesis through down-regulation of the c-Fos and nuclear factor of activated T cells c1 genes. Biol Pharm Bull 33: 133-137.
18. Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, et al. (2002). U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277: 47366-47372.
19. Jacobson KA, Gao ZG, (2006). Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5: 247-264.
20. Kara FM, Chitu V, Sloane J, Axelrod M, Fredholm BB, Stanley ER, et al. (2010a). Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function. FASEB J 24: 2325-2333.
21. Kara FM, Doty SB, Boskey A, Goldring S, Zaidi M, Fredholm BB, et al. (2010b). Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. Arthritis Rheum 62: 534-541.
22. Kharkwal G, Chandra V, Fatima I, Dwivedi A, (2012). Ormeloxifene inhibits osteoclast differentiation in parallel to downregulating RANKL-induced ROS generation and suppressing the activation of ERK and JNK in murine RAW264.7 cells. J Mol Endocrinol 48: 261-270.
23. Kondo H, Guo J, Bringhurst FR, (2002). Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J Bone Miner Res 17: 1667-1679.
24. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, et al. (2002). p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143: 3105-3113.
25. Londos C, Cooper DM, Wolff J, (1980). Subclasses of external adenosine receptors. Proc Natl Acad Sci U S A 77: 2551-2554.
26. Mazzon E, Esposito E, Impellizzeri D, DI Paola R, Melani A, Bramanti P, et al. (2011). CGS 21680, an agonist of the adenosine (A2A) receptor, reduces progression of murine type II collagen-induced arthritis. J Rheumatol 38: 2119-2129.
27. Mediero A, Frenkel SR, Wilder T, He W, Mazumder A, Cronstein BN, (2012a). Adenosine A2A receptor activation prevents wear particle-induced osteolysis. Sci Transl Med 4: 135ra165.
28. Mediero A, Kara FM, Wilder T, Cronstein BN, (2012b). Adenosine A(2A) receptor ligation inhibits osteoclast formation. Am J Pathol 180: 775-786.
29. Merrill JT, Shen C, Schreibman D, Coffey D, Zakharenko O, Fisher R, et al. (1997). Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum 40: 1308-1315.
30. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, et al. (2000). Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 148: 333-342.
31. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, et al. (2003). Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 48: 240-247.
32. Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, et al. (1998). Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 101: 295-300.
33. Pfaffl MW, (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
34. Saulnier N, Guihard S, Holy X, Decembre E, Jurdic P, Clay D, et al. (2012). ERK1 regulates the hematopoietic stem cell niches. PLoS ONE 7: e30788.
35. Schulte G, Fredholm BB, (2003). Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 15: 813-827.
36. Sexl V, Mancusi G, Holler C, Gloria-Maercker E, Schutz W, Freissmuth M, (1997). Stimulation of the mitogen-activated protein kinase via the A2A-adenosine receptor in primary human endothelial cells. J Biol Chem 272: 5792-5799.
37. Son YL, Ubuka T, Millar RP, Kanasaki H, Tsutsui K, (2012). Gonadotropin-inhibitory hormone inhibits GnRH-induced gonadotropin subunit gene transcriptions by inhibiting AC/cAMP/PKA-dependent ERK pathway in LbetaT2 cells. Endocrinology 153: 2332-2343.
38. Spirli C, Morell CM, Locatelli L, Okolicsanyi S, Ferrero C, Kim AK, et al. (2012). Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology 31: 25872.
39. Takada K, Kajiya H, Fukushima H, Okamoto F, Motokawa W, Okabe K, (2004). Calcitonin in human odontoclasts regulates root resorption activity via protein kinase A. J Bone Miner Metab 22: 12-18.
40. Tsubaki M, Satou T, Itoh T, Imano M, Yanae M, Kato C, et al. (2012). Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Mol Cell Endocrinol 631: 219-231.
41. Vaananen HK, Zhao H, Mulari M, Halleen JM, (2000). The cell biology of osteoclast function. J Cell Sci 113 (Pt 3): 377-381.
42. Verzijl D, Ijzerman AP, (2011). Functional selectivity of adenosine receptor ligands. Purinergic Signal 7: 171-192.
43. Wei S, Wang MW, Teitelbaum SL, Ross FP, (2002). Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J Biol Chem 277: 6622-6630.
44. Yang DC, Tsay HJ, Lin SY, Chiou SH, Li MJ, Chang TJ, et al. (2008). cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. PLoS ONE 3: e1540.
45. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, et al. (1999). A novel molecular mechanism modulating osteoclast differentiation and function. Bone 25: 109-113.
46. Yoon SH, Ryu JY, Lee Y, Lee ZH, Kim HH, (2011). Adenylate cyclase and calmodulin-dependent kinase have opposite effects on osteoclastogenesis by regulating the PKA-NFATc1 pathway. J Bone Miner Res 26: 1217-1229.